Moleculin Biotech shareholders approve issuance of up to 14.1M shares upon warrant exercise

Moleculin Biotech, Inc.

Proposal 1 (issuing up to 14,089,672 shares upon warrant exercise) passed: 5,627,617 for, 2,945,357 against, 4,784,514 abstain.
Proposal 2 (adjournment if needed) passed: 10,413,712 for, 2,866,539 against, 77,237 abstain.
Quorum of 39.97% (13,357,488 shares) achieved at Special Meeting on February 14, 2024.
Warrants were issued in a private placement that closed on December 26, 2023; shareholder vote was required under Nasdaq Listing Rules 5635(d).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Moleculin Biotech, Inc. shareholders approved Approval of issuance of up to 14,089,672 shares of common stock upon exercise of certain warrants as contemplated by Nasdaq Listing Rules 5635(d). at the 2024-02-14 meeting.

Outcome: passed
Meeting: 2024-02-14

Exact text from the filing

Proposal 1. The NASDAQ Proposal - The Company's stockholders approved the issuance of up to 14,089,672 shares of common stock upon the exercise of certain warrants issued in a private placement that closed on December 26, 2023, as contemplated by Nasdaq Listing Rules 5635(d), as described in more detail in the Proxy Statement, by the following vote: Votes For Votes Against Abstain 5,627,617 2,945,357 4,784,514

View on SEC.gov

219 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-004172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.